Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

UK preparing to meet 'inevitable' increased drug costs after US talks

Published by Global Banking and Finance Review

Posted on October 28, 2025

Featured image for article about Headlines

By Alistair Smout

LONDON (Reuters) -The British government is preparing to meet the "inevitable" increase in the cost of some drugs following talks over pharmaceutical sector pricing and tariffs with the United States, Science Minister Patrick Vallance said.

U.S. President Donald Trump has pressured Europe to pay more for U.S. drugs, and major pharma companies have halted investments in Britain, citing a difficult operating environment.

Vallance has acknowledged that the country's National Health Service needs to reverse a trend of declining spending on medicines, and on Tuesday he said that the ongoing talks with Washington would mean the costs of certain drugs would go up.

"I think that some degree of price increase is inevitable," he told lawmakers at a committee hearing, adding existing medicines and generics might not see the same increases.

"I think for brand new, innovative medicines, it's likely there will be some price increase."

UNCERTAINTY OVER US TALKS IMPACTS GOVERNMENT AND FIRMS

Asked if he was discussing the implications of such price increases on the state-run National Health Service with the health and finance ministries ahead of an annual government budget on November 26, Vallance said: "yes."

"We've discussed the fact that if there's a rise in price for innovative medicines, that comes with a cost load, and that needs to be met," Vallance said.

Vallance declined to comment on the details and latest status of the negotiations over pricing with the United States.

Amid uncertainty over those talks, the Association of the British Pharmaceutical Industry said pharmaceutical firms now had until November 14 to notify whether they intended to leave a voluntary pricing scheme, which has been a point of contention with the government.

ABPI said the two-week extension was "to give companies more time to consider their decisions in the context of ongoing global uncertainty affecting the life sciences sector."

Also under scrutiny in talks with the United States is Britain's framework for establishing the value for money of medicines, known as NICE.

Junior Health Minister Zubir Ahmed said there was no formal review looking at the NICE framework, but wanted to ensure it was "fit for the future" given concerns that the current system led to medical innovation being undervalued.

(Reporting by Alistair Smout; Editing by Sharon Singleton)